Biotech in Flanders - A Stunning Story ​ 

A new book reveals the secrets behind the success of the Flemish life sciences biotech industry

Ghent/Leuven, 13 November 2023 Flanders, the northern region of Belgium, is home to one of the most vibrant and innovative life sciences and biotech ecosystems in the world. Over the past 40 years, Flemish researchers and pioneers have made discoveries that today benefit over two million patients every year, and are used daily in agriculture, research labs and medical cabinets. How did this small region become a global leader in life sciences and biotechnology? What are the key factors that contributed to this remarkable development? Who are the pioneers and visionaries that shaped its history during the past 40 years? And what’s ahead for this thriving ecosystem? 

These are some of the questions that are answered in a new book, Biotech in Flanders - A Stunning Story, written by Jo Bury, Johan Cardoen and Dirk Reyn, three experts who have been closely involved in the Flemish biotech sector for decades. The book tells the fascinating story of how Flanders transformed itself into a world recognized biotech powerhouse, thanks to a fruitful cross-fertilization between high quality healthcare, excellent scientific research, daring entrepreneurship and industry collaboration, risky financing and a supportive government. 

Biotech in Flanders - A Stunning Story is a must-read for anyone interested in biotechnology, entrepreneurship, and regional biotech ecosystem development. 

The book is based upon more than 40 interviews, including many of the iconic figures of the Flemish biotech story who share their insights and experiences on the challenges and opportunities of almost half a century of biotech innovation. 

The book provides an overview of the current state and future prospects of the Flemish biotech industry, which counts several hundred of companies and employs some sixty thousand people, both in direct and supportingjobs. ​ 

Biotech in Flanders A Stunning Story offers an inspiring guide for those who want to gain insight into the ins and outs of an innovative and research-driven sector, working day after day on products that continually make the lives of millions of people safer, healthier and more sustainable. 

It is a stunning story, without question. It is also a tribute to the vision and passion of the people who made Flanders Biotech Valley a reality.

Published by Witsand Uitgevers (www.witsand.be), the book was created in collaboration with VIB (www.vib.be), flanders.bio (www.flanders.bio) and Flanders Investment & Trade (corporate.flandersinvestmentandtrade.com). It is available in Dutch and English.

Book available on www.biotechinflanders.com 

"Biotech in Flanders: A stunning story" now available for purchase

Joran Lauwers

Joran Lauwers

Press Contact, VIB

Share

Latest stories

Website preview
Blocking lipid production in healthy lung cells can reduce lung metastasis
Leuven, 17 March 2026 - Scientists from the VIB–KU Leuven Center for Cancer Biology, in collaboration with the Francis Crick Institute, have discovered how cancer cells can exploit healthy lung cells to support metastatic tumor growth in the lungs. In two complementary studies published in Nature Cell Biology and Cancer Discovery, they show that tumors use lipids produced by lung cells as signals, and that decreasing the lipid production of lung cells can decrease metastasis. The findings point to new therapeutic strategies that target lung cell lipid production, rather than cancer cells themselves, which may also help refine patient selection for ongoing clinical trials targeting this pathway.
press.vib.be
Website preview
Researchers identify major genetic risk factor for rare form of dementia
Antwerp, 12 March 2026 - Researchers at VIB and Antwerp University have identified a major genetic risk factor for a rare form of frontotemporal dementia. The discovery, published today in Nature Genetics, provides a biological entry point for a disease subtype that has been difficult to study. It could not only help to improve diagnosis and patient stratification, but also opens up new avenues toward targeted treatments.
press.vib.be
Website preview
Protealis Announces Regulatory Approval of its First Biological Solution MagNfixTM and Launch of Five New Soybean Varieties
Ghent (Belgium), 11 March 2026 – Protealis, the European specialist in non-GMO legume seeds and seed technologies, today announces several milestones that significantly strengthen its position in a fast-growing European soybean market. The company has obtained European regulatory approval from EFCI1 (EU Fertilising Products Regulation (FPR) 2019/1009) for MagNfix™, its first biological solution, which is a proprietary soybean inoculant seed coating that is designed to support higher soybean yield and protein content. In addition, Protealis has secured the registration of five new soybean varieties across four European countries. This includes the introduction of two new maturity group (MG) 000 soybean varieties in Poland, the registration of its first maturity group 0000 ultra-early soybean variety in France, and a new soy variety registration for Belgium. In Germany, Protealis received registration for its second 00 MG soybean variety suited for the regions in southern Germany...
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be